Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Dermatology

Understanding Linear IgA Dermatosis (LAD & CBDC)

At a Glance

Linear IgA dermatosis is a rare autoimmune blistering disease in which IgA antibodies mistakenly attack the layer that holds skin together. A dermatologist confirms it with a skin biopsy and direct immunofluorescence; in children, it is called chronic bullous disease of childhood (CBDC).

Finding out that you or your child has Linear IgA Dermatosis (LAD) often brings a mix of relief and confusion. You may have spent weeks or even months visiting different doctors, trying various creams for what looked like a stubborn infection or a strange allergic reaction, only to find the symptoms persisting or worsening [1][2]. This experience, often called a diagnostic odyssey, is common with rare diseases like LAD because the condition can look remarkably like more common issues such as chickenpox or standard skin infections [1][2].

LAD is an autoimmune blistering disease, meaning the immune system mistakenly attacks the “glue” that holds the layers of your skin together [3]. Specifically, it involves an antibody called IgA that deposits in a characteristic “linear” or straight-line pattern along the basement membrane of the skin [3][4]. When this occurs in children, it is often called Chronic Bullous Disease of Childhood (CBDC), though it is the same underlying disease process as adult LAD [5][4].

Understanding a Rare Diagnosis

Because LAD is exceptionally rare—affecting roughly 0.5 to 2.3 people per million each year—many local doctors and general practitioners may have never seen a case in person [6][7]. This rarity is why a specialist, usually a dermatologist, must confirm the diagnosis using a specific test called direct immunofluorescence (DIF) on a small sample of skin [3][8].

The disease follows what doctors call a bimodal age distribution, which is a fancy way of saying it tends to strike two distinct age groups [6][5]:

  • Children: Most cases begin between the ages of 2 and 5, though it can affect infants as well [5][9].
  • Adults: A second peak usually occurs later in life, often in the 60s [6][9].

The Three Main Contexts of LAD

While the symptoms of LAD—tense blisters that often form circular or “string of pearls” patterns—can look similar across different patients, doctors generally categorize the disease into three main types based on what might have triggered it [5][10]:

  1. Idiopathic (Unknown Cause): This is the most common form, where there is no clear outside trigger for the immune system’s confusion [3]. Idiopathic cases in adults can be chronic, sometimes lasting several years, and may require ongoing management to keep the skin clear [10][11].
  2. Drug-Induced: In some people, a medication triggers the reaction. Vancomycin, a powerful antibiotic, is the most frequently linked drug, with symptoms generally appearing after the medication is started [12][13][14]. Other medications, including certain NSAIDs (anti-inflammatories) and other antibiotics like amoxicillin, have also been reported as triggers [12][13]. It is crucial to review all recent medications with your clinician. The good news for these patients is that the condition often clears once the offending drug is safely stopped by the prescribing team [10].
  3. Malignancy-Associated: In rare instances, LAD can appear alongside an underlying internal health issue, such as certain types of blood or lymph node cancers [10][15]. Because of this, your doctor may perform routine age-appropriate screenings; however, this association is uncommon and does not mean LAD is inherently caused by cancer [10][16].

Navigating the Emotional Impact

The path to an LAD diagnosis can be exhausting. In adults, it can take an average of five months to get a definitive answer for the idiopathic form, during which time you may deal with intense itching, painful blisters, and the stress of not knowing what is wrong [10][17]. For parents of children with CBDC, the experience can be even more distressing, as the blisters often appear in sensitive areas like the face or groin and may require hospital stays for specialized care [18][19].

Acknowledging the toll this takes on your quality of life is an important part of your care [20]. Whether you are managing your own symptoms or caring for a child, the shift from “unknown infection” to “managed autoimmune condition” is a major milestone that allows you to stop searching for answers and start focusing on the right treatments [1]. Although the diagnosis feels overwhelming, having a name for the condition is the first step toward reclaiming control over your health [20][21].

Common questions in this guide

What is Linear IgA dermatosis, and is CBDC a different disease?
Linear IgA dermatosis is a rare autoimmune blistering disease in which IgA antibodies mistakenly attack the layer that holds the skin together. In children, it is often called chronic bullous disease of childhood (CBDC), but it is the same underlying disease process as LAD in adults.
How do doctors confirm a diagnosis of LAD?
A dermatologist usually confirms LAD with a small skin biopsy examined using direct immunofluorescence. This test looks for IgA deposited in a straight-line pattern along the skin’s basement membrane and helps distinguish LAD from other blistering diseases.
What do LAD blisters look and feel like?
LAD commonly causes tense blisters with intense itching or pain, and the blisters may form circular or string-of-pearls patterns. Because it can resemble chickenpox, a skin infection, or an allergic reaction, specialist evaluation is often important.
Can a medication such as vancomycin cause LAD?
Yes. Vancomycin is the medication most frequently linked with drug-induced LAD, and certain NSAIDs, amoxicillin, and other antibiotics have also been reported as triggers. Do not stop a prescribed medication without guidance; the prescribing clinician can decide whether it should be changed or stopped safely.
Does having LAD mean that I have cancer?
Usually not. Rarely, LAD occurs alongside certain blood or lymph node cancers, so a clinician may recommend routine, age-appropriate screening, but this association is uncommon and LAD is not inherently caused by cancer.
How long can Linear IgA dermatosis last?
The course varies by type. Drug-induced LAD often improves after the triggering medicine is safely stopped under medical supervision, while idiopathic LAD in adults can persist for several years and may need ongoing management.
When does LAD usually start in children and adults?
In children, most cases begin between ages 2 and 5, although infants can also be affected. In adults, a second peak often occurs in the 60s.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Linear IgA dermatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many cases of Linear IgA Dermatosis have you or this clinic treated before?
  2. 2.What specific evidence from my biopsy (such as direct immunofluorescence results) confirms this is LAD rather than another blistering condition?
  3. 3.Could any of my current medications, specifically vancomycin or antibiotics, be triggering this reaction?
  4. 4.Does my presentation look more like the 'idiopathic' form, or should we be looking for an underlying cause like a recent infection or other health condition?
  5. 5.What is the expected timeline for improvement once we begin the treatment plan?

References

References (21)
  1. 1

    The "Pearls" of Multidisciplinary Team: Conquering the Uncommon Rosette Rash.

    Verma N, Pickles C, Khan MA

    Case reports in pediatrics 2016; (2016()):5328603 doi:10.1155/2016/5328603.

    PMID: 28070436
  2. 2

    A Case of Linear IgA Bullous Dermatosis of Childhood With Ocular Involvement: A Diagnostic Challenge.

    Haidar H, Amos-Oluwole O, Loomba A, et al.

    Cornea 2026; (45(8)):1051-1055 doi:10.1097/ICO.0000000000004087.

    PMID: 42241023
  3. 3

    S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology.

    Caux F, Patsatsi A, Karakioulaki M, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2024; (38(6)):1006-1023 doi:10.1111/jdv.19880.

    PMID: 38421060
  4. 4

    Clinical characteristics and treatment outcomes of linear IgA bullous dermatosis.

    Mar K, Landells F, Khalid B, et al.

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2025; (23(5)):576-585 doi:10.1111/ddg.15644.

    PMID: 40018881
  5. 5

    Linear IgA bullous dermatosis in adults and children: a clinical and immunopathological study of 38 patients.

    Genovese G, Venegoni L, Fanoni D, et al.

    Orphanet journal of rare diseases 2019; (14(1)):115 doi:10.1186/s13023-019-1089-2.

    PMID: 31126328
  6. 6

    Linear IgA bullous dermatosis: a retrospective study of 23 patients in Denmark.

    Lings K, Bygum A

    Acta dermato-venereologica 2015; (95(4)):466-71 doi:10.2340/00015555-1990.

    PMID: 25350667
  7. 7

    Linear IgA Disease: A Rare Complication of Vancomycin.

    Saleem M, Iftikhar H

    Cureus 2019; (11(6)):e4848 doi:10.7759/cureus.4848.

    PMID: 31410331
  8. 8

    Case report: Dupilumab: a promising treatment option for adult linear IgA bullous dermatosis with severe pruritus.

    Wang L, Peng J, Chen J

    Frontiers in immunology 2024; (15()):1409556 doi:10.3389/fimmu.2024.1409556.

    PMID: 39161758
  9. 9

    Linear IgA bullous dermatosis: 32 years of experience.

    Atci T, Pehlivan Ulutas G, Güreler Sirkeci E, Küçükoğlu R

    Anais brasileiros de dermatologia 2025; (100(2)):277-282 doi:10.1016/j.abd.2024.03.015.

    PMID: 39665877
  10. 10

    Adult-onset linear IgA bullous dermatosis: a retrospective single-center cohort study of 81 patients and literature review.

    Wang KL, Lehman JS, Todd A, Davis DMR

    International journal of dermatology 2024; (63(7)):936-941 doi:10.1111/ijd.17041.

    PMID: 38251749
  11. 11

    Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults.

    Gottlieb J, Ingen-Housz-Oro S, Alexandre M, et al.

    The British journal of dermatology 2017; (177(1)):212-222 doi:10.1111/bjd.15244.

    PMID: 27995619
  12. 12

    Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases.

    Garel B, Ingen-Housz-Oro S, Afriat D, et al.

    British journal of clinical pharmacology 2019; (85(3)):570-579 doi:10.1111/bcp.13827.

    PMID: 30511379
  13. 13

    Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system.

    Yang Y, Xie H, Liu S, et al.

    Frontiers in medicine 2025; (12()):1521697 doi:10.3389/fmed.2025.1521697.

    PMID: 39917062
  14. 14

    Clinical characteristics, treatment, and outcomes of vancomycin-induced linear IgA bullous dermatosis.

    Wu Z, Sun W, Wang C

    Pharmacology 2026; 1-13 doi:10.1159/000552120.

    PMID: 42599841
  15. 15

    Linear IgA dermatosis in association with angioimmunoblastic T-cell lymphoma infiltrating the skin: A case report with literature review.

    Colmant C, Camboni A, Dekeuleneer V, et al.

    Journal of cutaneous pathology 2020; (47(3)):251-256 doi:10.1111/cup.13576.

    PMID: 31482600
  16. 16

    Linear IgA bullous dermatosis in an acute myeloid leukemia patient: a rare case report.

    Kianindra DV, Rosa A, Pebriany D, et al.

    Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2023; (32(1)):19-22.

    PMID: 36945763
  17. 17

    [Linear IgA bullous dermatosis].

    Juratli HA, Sárdy M

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2019; (70(4)):254-259 doi:10.1007/s00105-019-4377-9.

    PMID: 30874843
  18. 18

    Clinical features of chronic bullous dermatosis of childhood.

    Wilson A, Murrell DF

    Clinical and experimental dermatology 2022; (47(5)):873-881 doi:10.1111/ced.15059.

    PMID: 34919291
  19. 19

    Linear IgA bullous dermatosis of childhood: Retrospective single-center cohort.

    Wang KL, Lehman JS, Davis DMR

    Pediatric dermatology 2024; (41(3)):461-464 doi:10.1111/pde.15567.

    PMID: 38378007
  20. 20

    European S2k guidelines on management of autoimmune blistering diseases in children and adolescents.

    Nanda A, Tedbirt B, Bodemer C, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2026; (40(7)):1137-1161 doi:10.1111/jdv.70308.

    PMID: 41678328
  21. 21

    A Narrative Review of Pemphigoid Diseases: Bridging Associations, Comorbidities, and Management.

    Myers EL, Culton DA

    Dermatology and therapy 2025; (15(7)):1755-1770 doi:10.1007/s13555-025-01444-9.

    PMID: 40411679

This page about Linear IgA Dermatosis and Chronic Bullous Disease of Childhood is for informational purposes only and does not constitute medical advice. A dermatologist should interpret biopsy results and guide care for your specific situation.